Stay tuned on the latest company news and upcoming events

JUNE 30, 2021
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

APRIL 06, 2021
Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

JUNE 10, 2020
Azafaros expands executive management team and operations

FEBRUARY 06, 2020
Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

JULY 23, 2018
Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders

National Tay-Sachs & Allied Diseases Association, 22-25th April, 2021
2021 Annual Family Conference
https://ntsad.org/index.php/2021-annual-family-conference

ICIEM, 21-23rd November, 2021
Virtual Meeting
https://iciem2021.com.au/